Combining the power of nature and genomics to create new medicines

DemurisTM has a large portfolio of drug projects and state-of-the-art platform technologies in natural product discovery, design and production

The rise in drug resistant pathogens is causing serious health concerns and an increasing economic burden. There is a growing demand for new agents to treat these evolving diseases. Demuris is developing a suite of new antibiotic compounds active in key areas of unmet medical need.

The starting points for Demuris’ portfolio of new drug project portfolio lies in a unique collection of Actinomycete bacteria. These organisms specialise in making natural product (NP) compounds with powerful biological activities that kill or manipulate the behaviour of surrounding organisms, including bacteria, fungi, plants and animals.

Demuris is also developing advanced molecular biology and synthetic biology methods to identify new NPs, and manipulate them to make better drug-like molecules and at much higher yields.

Demuris can also offer its technology platform as a service for academics and companies wishing to discover and develop new drugs.

... only a fraction of the natural products that these bacteria are capable of making has been screened

Demuris Limited
Newcastle Biomedicine Bio-Incubators,
Faculty of Medical Sciences, Framlington Place,
Newcastle upon Tyne, NE2 4HH, UK

Tel: +44 (0)191 223 5608
Fax: +44 (0)191 223 5609

Demuris Limited is registered in England, company number: 06255507

Demuris Limited 2015